Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 6, 1999, Pages 787-790

  Shadkchan, Yona ^a   Segal, Esther ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MOUSE; NONHUMAN; SPLEEN; SURVIVAL; TISSUE HOMOGENATE;

EID: 0032786098     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.6.787     Document Type: Article

References (13)

1. Shadkhan, Y., Segal, E., Bor, A., Gov, Y., Rubin, M. &Lichtenberg, D. (1997). The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. Journal of Antimicrobial Chemotherapy 39, 655-8.
2. Gallis, H. A. (1996). Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clinical Infectious Diseases 22, Suppl. 2, s145-7.
3. Graybill, J. R., Revankar, S. G. & Patterson, T. F. (1998). Systemic antifungal drugs in current use. In Microbiology and Microbial Infections. 9th edn, (Topley & Wilson, Eds), pp. 163-5. Arnold, Great Britain.
4. Brajtburg, J. & Bolard, J. (1996). Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews 9, 512-31.
5. Sabra, R. & Branch, R. A. (1990). Amphotericin B nephrotoxicity. Drug Safety 5, 94-108.
6. Gates, C. & Pinney, R. J. (1993). Amphotericin B and its delivery by liposomal and lipid formulations. Journal of Clinical Pharmacy and Therapeutics 8, 147-53.
7. Brajtburg, J., Powderly, W. G., Kobayashi, G. S. & Medoff, G. (1990). Amphotericin B: Delivery systems. Antimicrobial Agents and Chemotherapy 34, 381-4.
8. Janoff, A. S. (1990). Liposomes and lipid structures as carriers of amphotericin B. Journal of Clinical Microbiology and Infectious Diseaseses 9, 146-51.
9. Hiemenz, J. W. & Walsh, T. J. (1996). Lipid formulations of Amphotericin B: recent progress and future directions. Clinical Infectious Diseases 22, Suppl. 2, S133-44.
10. Levy, R., Segal, E. & Eylan, E. (1981). Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions. Infection and Immunity 31, 874-8.
11. Levy, M. Y., Polachek, I., Barenholz, Y. & Benita, S. (1993). Efficacy evaluation of a novel submicron Amphotericin B emulsion in murine candidiasis. Journal of Medical and Veterinary Mycology 31, 207-18.
12. Ryley, J. F. (1990). Screening and evaluation in vivo. In Handbook of Experimental Pharmacology. Chemotherapy of Fungal Diseases. Vol 96, (Ryley, J. F., Ed.) pp. 129-36. Springer-Verlag, Germany.
13. Anaissiae, E. J., Pinczowski, H. & Louria, D. B. (1993). Candida infections in experimental animals. In Candidiasis: Pathogenesis, Diagnosis and Treatment. 2nd edn, (Bodey, Ed.), pp. 43-57. Raven Press, New York.